Simultaneous Measurement of two Serum Markers (CA-125 and HE-4) while Diagnosing Malignant Ovarian Epithelial Tumors
Abstract
Objective: To evaluate the benefits of simultaneous measurement of CA-125 and HE-4 markers while diagnosing malignant epithelial tumors in the ovary. By this, the combined measurement of serum markers will possibly add to the accuracy of diagnosing such ovarian tumor.
Methodology: Performing a cross- sectional study on 87 women with ovarian mass, serum levels of CA125 and HE4 markers were measured before surgery or biopsy. In the wake of the surgery or biopsy, the results obtained from these tests were compared and analyzed with pathological report.
Results: The average serum level of CA-125 and HE-4 serum was notably higher in women with ovarian malignancy than in those with benignancy (CA-125: 502 vs. 19.3 v/ml, P < 0.001- HE4: 195 vs. 15.8 P mol/L, P < 0.001). As the disease stage rises, the level of these markers increases significantly. The two markers were also directly proportionate. (r = 0.85 and P < 0.001). There is also a meaningful difference between the levels of markers, specifically HE-4, in epithelial and non-epithelial tumors of ovary (HE-4: 195 vs. 93 P mol/L P < 0.001). The simultaneous measurement of CA-125 and HE-4 increases the sensitivity and specificity of diagnosing malignant epithelial tumors in ovary, compared with one- by- one measurement guideline. The sensitivity and specificity of simultaneous measurement of CA125 and HE4 for diagnosing epithelial ovarian cancer were calculated to be 99.5% and 100%, respectively.
Conclusion: Simultaneous measurement of CA-125 and HE-4 increases the sensitivity and keep the specificity still high in diagnosing malignant epithelial tumors in ovary, compared with one-by-one measurement system.
Methodology: Performing a cross- sectional study on 87 women with ovarian mass, serum levels of CA125 and HE4 markers were measured before surgery or biopsy. In the wake of the surgery or biopsy, the results obtained from these tests were compared and analyzed with pathological report.
Results: The average serum level of CA-125 and HE-4 serum was notably higher in women with ovarian malignancy than in those with benignancy (CA-125: 502 vs. 19.3 v/ml, P < 0.001- HE4: 195 vs. 15.8 P mol/L, P < 0.001). As the disease stage rises, the level of these markers increases significantly. The two markers were also directly proportionate. (r = 0.85 and P < 0.001). There is also a meaningful difference between the levels of markers, specifically HE-4, in epithelial and non-epithelial tumors of ovary (HE-4: 195 vs. 93 P mol/L P < 0.001). The simultaneous measurement of CA-125 and HE-4 increases the sensitivity and specificity of diagnosing malignant epithelial tumors in ovary, compared with one- by- one measurement guideline. The sensitivity and specificity of simultaneous measurement of CA125 and HE4 for diagnosing epithelial ovarian cancer were calculated to be 99.5% and 100%, respectively.
Conclusion: Simultaneous measurement of CA-125 and HE-4 increases the sensitivity and keep the specificity still high in diagnosing malignant epithelial tumors in ovary, compared with one-by-one measurement system.
Refbacks
- There are currently no refbacks.
